Graham Lidgard is the Chief Scientific Officer, Emeritus at Exact Sciences, with a Ph. D. from The University of Manchester. A veteran R&D leader from roles at Gen-Probe and Nanogen, he was instrumental in the development and successful FDA approval of the pioneering Cologuard cancer screening test.
He led the research team whose pivotal study on Cologuard was published in the prestigious New England Journal of Medicine.
Graham Lidgard
CSO Emeritus at Exact Sciences
Madison, Wisconsin, United States
Overview
Topics They Care About
Cancer Diagnostics
His career has been dedicated to developing noninvasive screening tests for early cancer detection, most notably Cologuard at Exact Sciences.
R&D Leadership
Has a long history of leading research and development teams at prominent diagnostic companies, including Gen-Probe, Nanogen, and Exact Sciences.
Clinical Validation
He successfully guided the large-scale DeeP-C study for Cologuard, leading to its publication in The New England Journal of Medicine.
Media Appearances
Exact Sciences Corporation Announces Appointment of Diagnostics Veteran Graham Lidgard, PhD, as Chief Scientific Officer. Featured in BioSpace
Work History
4-2021
CSO Emeritus at Exact Sciences
8-2009
Senior Vice President R&D and Chief Scientific Officer at Exact Sciences
1-2003 - 7-2009
Senior Vice President, R&D at Nanogen
VP R&D at Gen-Probe
VP R&D at Matritech Inc
Program Manager; Manager, Business Development and others at Ciba Corning Diagnostics Corp. Walpole, MA
Education
1970 - 1973
Ph.D from The University of Manchester
1967 - 1970
B.Sc. from The University of Manchester
More Information
Social Presence :
Prographics :
Exp : 23
Location : Madison, Wisconsin, United States
Job Level : Leadership
Designation : CSO Emeritus at Exact Sciences
